Kelly Chin

7.5k total citations · 4 hit papers
137 papers, 4.9k citations indexed

About

Kelly Chin is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Kelly Chin has authored 137 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Pulmonary and Respiratory Medicine, 58 papers in Cardiology and Cardiovascular Medicine and 20 papers in Genetics. Recurrent topics in Kelly Chin's work include Pulmonary Hypertension Research and Treatments (116 papers), Heart Failure Treatment and Management (22 papers) and Cardiovascular Issues in Pregnancy (21 papers). Kelly Chin is often cited by papers focused on Pulmonary Hypertension Research and Treatments (116 papers), Heart Failure Treatment and Management (22 papers) and Cardiovascular Issues in Pregnancy (21 papers). Kelly Chin collaborates with scholars based in United States, Switzerland and Germany. Kelly Chin's co-authors include Lewis J. Rubin, Richard N. Channick, Robert Naeije, Vallerie V. McLaughlin, Fernando Torres, Paul M. Hassoun, Steven M. Kawut, Joost Lumens, Anton Vonk Noordegraaf and François Haddad and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Communications.

In The Last Decade

Kelly Chin

123 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Right Heart Adaptation to Pulmonary Arterial Hypertension

2013 706 citations Kelly Chin, Paul M. Hassoun et al. Journal of the American College of Cardiology profile →
Selexipag for the Treatment of Pulmonary Arterial Hypertension

2015 706 citations Olivier Sitbon, Richard N. Channick et al. profile →
Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update

2018 349 citations Kelly Chin, Paul M. Hassoun et al. European Respiratory Journal profile →
Treatment algorithm for pulmonary arterial hypertension

2024 50 citations Kelly Chin, Stephen C. Mathai et al. European Respiratory Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kelly Chin United States	30	4.0k	2.8k	569	517	479	137	4.9k
Carmine Dario Vizza Italy	34	3.8k 1.0×	3.2k 1.1×	578 1.0×	686 1.3×	495 1.0×	214	4.9k
Michael Halank Germany	33	4.3k 1.1×	3.0k 1.0×	442 0.8×	578 1.1×	513 1.1×	153	5.0k
Gábor Kovács Austria	39	3.4k 0.9×	2.4k 0.8×	469 0.8×	421 0.8×	254 0.5×	133	4.4k
Myung H. Park United States	22	3.1k 0.8×	2.9k 1.0×	486 0.9×	987 1.9×	471 1.0×	64	4.5k
Anna R. Hemnes United States	44	5.8k 1.5×	4.1k 1.4×	728 1.3×	896 1.7×	478 1.0×	222	7.2k
Paul R. Forfia United States	34	4.1k 1.0×	4.1k 1.4×	1.1k 1.9×	851 1.6×	261 0.5×	114	5.9k
Pavel Jansa Czechia	27	4.9k 1.2×	3.8k 1.3×	310 0.5×	381 0.7×	1.1k 2.4×	153	5.5k
Ioana R. Preston United States	31	3.2k 0.8×	2.1k 0.8×	227 0.4×	514 1.0×	466 1.0×	106	3.8k
Tomás Pulido Mexico	28	5.9k 1.5×	4.2k 1.5×	785 1.4×	630 1.2×	1.2k 2.5×	93	6.5k
James R. Klinger United States	36	3.6k 0.9×	2.3k 0.8×	435 0.8×	648 1.3×	443 0.9×	136	5.0k

Countries citing papers authored by Kelly Chin

Since Specialization

Citations

This map shows the geographic impact of Kelly Chin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelly Chin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelly Chin more than expected).

Fields of papers citing papers by Kelly Chin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelly Chin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelly Chin. The network helps show where Kelly Chin may publish in the future.

Co-authorship network of co-authors of Kelly Chin

This figure shows the co-authorship network connecting the top 25 collaborators of Kelly Chin. A scholar is included among the top collaborators of Kelly Chin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelly Chin. Kelly Chin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fan, Fenling, Stacy N. Davis, Kelly Chin, et al.. (2025). Single-Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study of the A DUE Phase 3 Trial. Advances in Therapy. 42(5). 2298–2313. 1 indexed citations

Farber, Harrison W., Murali M. Chakinala, Anna R. Hemnes, et al.. (2025). Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity. Journal of Racial and Ethnic Health Disparities.

Humbert, Marc, Paul M. Hassoun, Kelly Chin, et al.. (2024). MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study. European Respiratory Journal. 64(5). 2401110–2401110. 3 indexed citations

Chin, Kelly, et al.. (2024). Effect on Exercise Capacity and Long-Term Safety and Tolerability of Macitentan and Tadalafil as a Single-tablet Combination in Patients With Pulmonary Arterial Hypertension From the A DUE Open-label Interim Analysis. A1016–A1016. 1 indexed citations

Yip, J, Adrian Oo, Kelly Chin, et al.. (2024). The role of inflammatory gene polymorphisms in severe COVID-19: a review. Virology Journal. 21(1). 327–327. 3 indexed citations

Chin, Kelly, Richard N. Channick, Nick H. Kim, et al.. (2024). Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies. Cardiology and Therapy. 13(4). 775–796. 1 indexed citations

Chin, Kelly, et al.. (2024). CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TRANSITIONING TO SELEXIPAG FROM ANOTHER PROSTACYCLIN PATHWAY AGENT IN THE SPHERE REGISTRY. CHEST Journal. 166(4). A5806–A5811. 1 indexed citations

McLaughlin, Vallerie V., Harrison W. Farber, Kristin B. Highland, et al.. (2023). Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry). The Journal of Heart and Lung Transplantation. 43(2). 272–283. 9 indexed citations

Shah, Trushil, et al.. (2023). Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy. Pulmonary Circulation. 13(2). e12226–e12226. 3 indexed citations

10.

Chin, Kelly, William R. Auger, Raymond L. Benza, et al.. (2023). Long-term Survival and Quality of Life. 1(2). 100008–100008. 6 indexed citations

11.

Chin, Kelly, et al.. (2023). Outcomes After Supraventricular Tachycardia Ablation in Patients With Group 1 Pulmonary Hypertension. Cardiology Research. 14(5). 403–408. 1 indexed citations

12.

Bartolome, Sonja, et al.. (2022). Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag. SHILAP Revista de lepidopterología. 7(3). 115–124. 2 indexed citations

13.

Liberman, Tara, et al.. (2021). Remote Advance Care Planning in the Emergency Department During COVID-19 Disaster: Program Development and Initial Evaluation. Journal of Emergency Nursing. 48(1). 22–31. 9 indexed citations

14.

Galiè, Nazzareno, Olivier Sitbon, Martin Doelberg, et al.. (2020). Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: insights from the randomised controlled TRITON study. European Heart Journal. 41(Supplement_2). 2 indexed citations

15.

McLaughlin, Vallerie V., Richard Channick, Kelly Chin, et al.. (2018). THE OPSUMIT® USERS REGISTRY: A GENDER SUBGROUP ANALYSIS OF PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND SURVIVAL IN PULMONARY ARTERIAL HYPERTENSION. Journal of the American College of Cardiology. 71(11). A1952–A1952. 2 indexed citations

16.

Mercurio, Valentina, Monica Mukherjee, Ryan J. Tedford, et al.. (2017). Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 197(3). 388–391. 29 indexed citations

17.

Pandey, Ambarish, Sushil Kumar Garg, Monica Khunger, et al.. (2015). Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension. Circulation Heart Failure. 8(6). 1032–1043. 83 indexed citations

18.

Hassoun, Paul M., Roham T. Zamanian, Rachel L. Damico, et al.. (2015). Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 192(9). 1102–1110. 114 indexed citations

19.

Matulevicius, Susan, et al.. (2013). CARDIAC MRI PREDICTORS OF MORTALITY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Journal of the American College of Cardiology. 61(10). E1255–E1255. 1 indexed citations

20.

Cronkhite, Jennifer T., Chao Xing, Ganesh Raghu, et al.. (2008). Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 178(7). 729–737. 385 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact